The protease Omi regulates mitochondrial biogenesis through the GSK3β/PGC-1α pathway

Cell Death and Disease

Volumn 5, Issue 8, 2014, Pages

  Xu, R ^a   Hu, Q ^b   Ma, Q ^b   Liu, C ^c   Wang, G ^a,b  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b College of Pharmaceutical Sciences   (China)

^c SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; GSK3B PROTEIN, HUMAN; GSK3B PROTEIN, MOUSE; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PPARGC1A PROTEIN, MOUSE; SERINE PROTEINASE; SERINE PROTEINASE OMI; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MITOCHONDRIAL DYNAMICS; MITOCHONDRION; MOUSE; PROTEIN DEGRADATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BRAIN; CELL LINE, TUMOR; DNA, MITOCHONDRIAL; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; INDOLES; MALEIMIDES; MICE; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; MITOCHONDRIAL TURNOVER; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA; PROTEOLYSIS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84906851501     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.328     Document Type: Article

References (60)

1. Nicholls DG, Budd SL. Mitochondria and neuronal survival. Physiol Rev 2000; 80: 315-360.
2. Van Laar VS, Berman SB. The interplay of neuronal mitochondrial dynamics and bioenergetics: implications for Parkinson's disease. Neurobiol Dis 2013; 51: 43-55.
3. Anne Stetler R, Leak RK, Gao Y, Chen J. The dynamics of the mitochondrial organelle as a potential therapeutic target. J Cereb Blood Flow Metab 2013; 33: 22-32.
4. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443: 787-795.
5. Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 2006; 7: 207-219.
6. Wu Y, Le W, Jankovic J. Preclinical biomarkers of Parkinson disease. Arch Neurol 2011; 68: 22-30.
7. Wang X, Yan MH, Fujioka H, Liu J, Wilson-Delfosse A, Chen SG et al. LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet 2012; 21: 1931-1944.
8. Kuroda Y, Mitsui T, Kunishige M, Shono M, Akaike M, Azuma H et al. Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet 2006; 15: 883-895.
9. Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 2008; 183: 795-803.
10. Fornai F, Schluter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci USA 2005; 102: 3413-3418.
11. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000; 3: 1301-1306.
12. Gray CW, Ward RV, Karran E, Turconi S, Rowles A, Viglienghi D et al. Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response. Eur J Biochem 2000; 267: 5699-5710.
13. Hartkamp J, Carpenter B, Roberts SG. The Wilms' tumor suppressor protein WT1 is processed by the serine protease HtrA2/Omi. Mol Cell 2010; 37: 159-171.
14. Suzuki Y, Imai Y, Nakayama H, Takahashi K, Takio K, Takahashi R. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell 2001; 8: 613-621.
15. Blink E, Maianski NA, Alnemri ES, Zervos AS, Roos D, Kuijpers TW. Intramitochondrial serine protease activity of Omi/HtrA2 is required for caspase-independent cell death of human neutrophils. Cell Death Differ 2004; 11: 937-939.
16. Liu MJ, Liu ML, Shen YF, Kim JM, Lee BH, Lee YS et al. Transgenic mice with neuronspecific overexpression of HtrA2/Omi suggest a neuroprotective role for HtrA2/Omi. Biochem Biophys Res Commun 2007; 362: 295-300.
17. Jones JM, Datta P, Srinivasula SM, Ji W, Gupta S, Zhang Z et al. Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice. Nature 2003; 425: 721-727.
18. Rathke-Hartlieb S, Schlomann U, Heimann P, Meisler MH, Jockusch H, Bartsch JW. Progressive loss of striatal neurons causes motor dysfunction in MND2 mutant mice and is not prevented by Bcl-2. Exp Neurol 2002; 175: 87-97.
19. Martins LM, Morrison A, Klupsch K, Fedele V, Moisoi N, Teismann P et al. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol 2004; 24: 9848-9862.
20. Strauss KM, Martins LM, Plun-Favreau H, Marx FP, Kautzmann S, Berg D et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 2005; 14: 2099-2111.
21. Bogaerts V, Nuytemans K, Reumers J, Pals P, Engelborghs S, Pickut B et al. Genetic variability in the mitochondrial serine protease HTRA2 contributes to risk for Parkinson disease. Hum Mutat 2008; 29: 832-840.
22. Kang S, Louboutin JP, Datta P, Landel CP, Martinez D, Zervos AS et al. Loss of HtrA2/Omi activity in non-neuronal tissues of adult mice causes premature aging. Cell Death Differ 2013; 20: 259-269.
23. Plun-Favreau H, Klupsch K, Moisoi N, Gandhi S, Kjaer S, Frith D et al. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat Cell Biol 2007; 9: 1243-1252.
24. Inagaki R, Tagawa K, Qi ML, Enokido Y, Ito H, Tamura T et al. Omi / HtrA2 is relevant to the selective vulnerability of striatal neurons in Huntington's disease. Eur J Neurosci 2008; 28: 30-40.
25. Tain LS, Chowdhury RB, Tao RN, Plun-Favreau H, Moisoi N, Martins LM et al. Drosophila HtrA2 is dispensable for apoptosis but acts downstream of PINK1 independently from Parkin. Cell Death Differ 2009; 16: 1118-1125.
26. Hock MB, Kralli A. Transcriptional control of mitochondrial biogenesis and function. Annu Rev Physiol 2009; 71: 177-203.
27. Ventura-Clapier R, Garnier A, Veksler V. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. Cardiovasc Res 2008; 79: 208-217.
28. Olson BL, Hock MB, Ekholm-Reed S, Wohlschlegel JA, Dev KK, Kralli A et al. SCFCdc4 acts antagonistically to the PGC-1alpha transcriptional coactivator by targeting it for ubiquitin-mediated proteolysis. Genes Dev 2008; 22: 252-264.
29. Anderson RM, Barger JL, Edwards MG, Braun KH, O'Connor CE, Prolla TA et al. Dynamic regulation of PGC-1alpha localization and turnover implicates mitochondrial adaptation in calorie restriction and the stress response. Aging Cell 2008; 7: 101-111.
30. Li Y, Chen J, Wang L, Zhang L, Lu M, Chopp M. Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson's disease. Neurosci Lett 2001; 316: 67-70.
31. Diaz F, Moraes CT. Mitochondrial biogenesis and turnover. Cell Calcium 2008; 44: 24-35.
32. Onyango IG, Lu J, Rodova M, Lezi E, Crafter AB, Swerdlow RH. Regulation of neuron mitochondrial biogenesis and relevance to brain health. Biochim Biophys Acta 2010; 1802: 228-234.
33. Lin TK, Liou CW, Chen SD, Chuang YC, Tiao MM, Wang PW et al. Mitochondrial dysfunction and biogenesis in the pathogenesis of Parkinson's disease. Chang Gung Med J 2009; 32: 589-599.
34. Keeney PM, Dunham LD, Quigley CK, Morton SL, Bergquist KE, Bennett JP Jr. Cybrid models of Parkinson's disease show variable mitochondrial biogenesis and genotype-respiration relationships. Exp Neurol 2009; 220: 374-382.
35. Ekstrand MI, Terzioglu M, Galter D, Zhu S, Hofstetter C, Lindqvist E et al. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci USA 2007; 104: 1325-1330.
36. Handschin C. The biology of PGC-1alpha and its therapeutic potential. Trends Pharmacol Sci 2009; 30: 322-329.
37. Jones AW, Yao Z, Vicencio JM, Karkucinska-Wieckowska A, Szabadkai G. PGC-1 family coactivators and cell fate: roles in cancer, neurodegeneration, cardiovascular disease and retrograde mitochondria-nucleus signalling. Mitochondrion 2012; 12: 86-99.
38. Clark J, Reddy S, Zheng K, Betensky RA, Simon DK. Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson's disease. BMC Med Genet 2011; 12: 69.
39. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006; 127: 59-69.
40. Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 2011; 144: 689-702.
41. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2010; 2: 52ra73.
42. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006; 127: 397-408.
43. Lin J, Wu PH, Tarr PT, Lindenberg KS, St-Pierre J, Zhang CY et al. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 2004; 119: 121-135.
44. Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S et al. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 2005; 3: e101.
45. Li B, Hu Q, Wang H, Man N, Ren H, Wen L et al. Omi/HtrA2 is a positive regulator of autophagy that facilitates the degradation of mutant proteins involved in neurodegenerative diseases. Cell Death Differ 2010; 17: 1773-1784.
46. Hu Q, Li B, Xu R, Chen D, Mu C, Fei E et al. The protease Omi cleaves the mitogenactivated protein kinase kinase MEK1 to inhibit microglial activation. Sci Signal 2012; 5: ra61.
47. Valerio A, Bertolotti P, Delbarba A, Perego C, Dossena M, Ragni M et al. Glycogen synthase kinase-3 inhibition reduces ischemic cerebral damage, restores impaired mitochondrial biogenesis and prevents ROS production. J Neurochem 2011; 116: 1148-1159.
48. Kwok JB, Hallupp M, Loy CT, Chan DK, Woo J, Mellick GD et al. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol 2005; 58: 829-839.
49. Wills J, Jones J, Haggerty T, Duka V, Joyce JN, Sidhu A. Elevated tauopathy and alphasynuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 2010; 225: 210-218.
50. Lei P, Ayton S, Bush AI, Adlard PA. GSK-3 in neurodegenerative diseases. Int J Alzheimers Dis 2011; 2011: 189246.
51. Armentero MT, Sinforiani E, Ghezzi C, Bazzini E, Levandis G, Ambrosi G et al. Peripheral expression of key regulatory kinases in Alzheimer's disease and Parkinson's disease. Neurobiol Aging 2011; 32: 2142-2151.
52. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B et al. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 1999; 58: 1010-1019.
53. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 2001; 20: 27-39.
54. Petit-Paitel A, Brau F, Cazareth J, Chabry J. Involvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neurons. PLoS One 2009; 4: e5491.
55. Martel C, Allouche M, Esposti DD, Fanelli E, Boursier C, Henry C et al. Glycogen synthase kinase 3-mediated voltage-dependent anion channel phosphorylation controls outer mitochondrial membrane permeability during lipid accumulation. Hepatology 2013; 57: 93-102.
56. Mao Y, Ge X, Frank CL, Madison JM, Koehler AN, Doud MK et al. Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell 2009; 136: 1017-1031.
57. Gan B, Hu J, Jiang S, Liu Y, Sahin E, Zhuang L et al. Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature 2010; 468: 701-704.
58. Evdokimovsky EV, Ushakova TE, Kudriavtcev AA, Gaziev AI. Alteration of mtDNA copy number, mitochondrial gene expression and extracellular DNA content in mice after irradiation at lethal dose. Radiat Environ Biophys 2011; 50: 181-188.
59. Strum JC, Shehee R, Virley D, Richardson J, Mattie M, Selley P et al. Rosiglitazone induces mitochondrial biogenesis in mouse brain. J Alzheimers Dis 2007; 11: 45-51.
60. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999; 98: 115-124.